Cryptotanshinone Inhibits STAT3 Signaling to Alleviate Cardiac Fibrosis in Type 1-like Diabetic Rats

Lo, Sherman; Hsu, Chao‐Tien; Niu, Ho‐Shan; Niu, Chiang‐Shan; Chen, Zhih‐Cherng

doi:10.1002/ptr.5777

Cited by 40 publications

(30 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, researchers found more biofunctions of CTS. For example, CTS alleviated cardiac fibrosis in type 1‐like diabetic rats . In addition, CTS ameliorated synovitis and prevented joint damage of rats with type 2 collagen‐induced arthritis .…”

Section: Discussionmentioning

confidence: 97%

Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3

Tang

Wang

et al. 2018

Experimental Dermatology

View full text Add to dashboard Cite

The discovery of new therapeutic drugs with the efficacious and safe ability to prevent epidermal hyperplasia is extremely urgent for psoriasis. Cryptotanshinone (CTS), an active component isolated from the root of Salvia miltiorrhiza Bunge, has been reported to have antibacterial and antitumor effects. However, its effects on psoriasis have not been reported. Here, we investigated the therapeutic effects of CTS on imiquimod (IMQ)-induced psoriatic-like skin model and explored the underlying mechanisms. Our results revealed that CTS effectively alleviates IMQ-induced epidermal hyperplasia. In vitro studies also indicated that CTS potently inhibits the growth of keratinocytes. We further found that STAT3, a transcription factor for the cell growth, is the key mediator of CTS on the proliferation of keratinocytes. Taken together, our findings indicated that the curative effects of CTS on psoriasis are accomplished mainly through modulating STAT3, which providing evidences to develop CTS as a potential therapeutic agent for patients with psoriasis.

show abstract

Section: Discussionmentioning

confidence: 97%

Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3

Tang

Wang

et al. 2018

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Among all these factors, myocardial fibrosis is the most frequently proposed mechanism to explain cardiac changes in DCM. Many studies have shown that inhibiting myocardial fibrosis can attenuate the progress of DCM in animal experiments (16,17).…”

Section: Discussionmentioning

confidence: 99%

Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts

et al. 2018

View full text Add to dashboard Cite

Cardiac fibrosis is a major pathological manifestation of diabetic cardiomyopathy (DCM), which leads to cardiac remodeling, dilated cardiomyopathy and congestive heart failure. Human cardiac fibroblasts (HCF) constitute the predominant cell type in the heart and matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are also involved in cardiac fibrosis. However, it is unclear whether high glucose levels affect the expression of MMPs and TIMPs in HCF. Sodium‑glucose cotransporter (SGLT) inhibitors have been developed as therapeutic agents and the anti‑DCM effect of SGLT inhibitors has been demonstrated by previous studies. However, whether SLGT inhibitors protect the diabetic heart by directly inhibiting the SGLTs in HCF in addition to lowering the blood glucose levels, has not yet been determined. In the present study, increased MMP‑2 expression was noted in HCFs in response to high glucose levels, which may be reversed by phlorizin (inhibits both SGLT1 and SGLT2), but not dapagliflozin (inhibits SGLT2). In addition, SGLT1 was revealed to be present in the HCFs and high glucose level was demonstrated to increase SGLT1 expression, which may be attenuated by phlorizin. Therefore it was concluded that high glucose levels induced MMP‑2 expression in the HCFs, potentially by upregulating SGLT1. SGLT1 inhibition may be a novel strategy for the treatment of DCM.

show abstract

“…Cryptotanshinone is an active principal ingredient isolated from Salvia miltiorrhiza (Danshen). Oral administration of 10 mg/kg/d cryptotanshinone for 28 days attenuates the cardiac fibrosis in STZ-induced diabetic rats by inhibiting STAT3 pathway and MMP-9 expression [ 87 ].…”

Section: Herbal Medicines: Promising Therapeutic For Dcmmentioning

confidence: 99%

Roles and Mechanisms of Herbal Medicine for Diabetic Cardiomyopathy: Current Status and Perspective

Tian

Zhao

Liu

et al. 2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Diabetic cardiomyopathy is one of the major complications among patients with diabetes mellitus. Diabetic cardiomyopathy (DCM) is featured by left ventricular hypertrophy, myocardial fibrosis, and damaged left ventricular systolic and diastolic functions. The pathophysiological mechanisms include metabolic-altered substrate metabolism, dysfunction of microvascular, renin-angiotensin-aldosterone system (RAAS) activation, oxidative stress, cardiomyocyte apoptosis, mitochondrial dysfunction, and impaired Ca2+ handling. An array of molecules and signaling pathways such as p38 mitogen-activated protein kinase (p38 MAPK), c-Jun N-terminal kinase (JNK), and extracellular-regulated protein kinases (ERK) take roles in the pathogenesis of DCM. Currently, there was no remarkable effect in the treatment of DCM with application of single Western medicine. The myocardial protection actions of herbs have been gearing much attention. We present a review of the progress research of herbal medicine as a potential therapy for diabetic cardiomyopathy and the underlying mechanisms.

show abstract

Cryptotanshinone Inhibits STAT3 Signaling to Alleviate Cardiac Fibrosis in Type 1-like Diabetic Rats

Cited by 40 publications

References 38 publications

Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3

Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3

Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts

Roles and Mechanisms of Herbal Medicine for Diabetic Cardiomyopathy: Current Status and Perspective

Contact Info

Product

Resources

About